What is the appropriate treatment for Staphylococcus lugdunensis infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment of Staphylococcus lugdunensis Infection

Treat Staphylococcus lugdunensis infections with the same aggressive approach as Staphylococcus aureus, using beta-lactam antibiotics (nafcillin, oxacillin, or cefazolin) for 4-6 weeks for serious infections, as this organism is typically methicillin-susceptible but exhibits S. aureus-like virulence.

Key Clinical Principle

S. lugdunensis is a coagulase-negative staphylococcus that behaves like S. aureus in terms of virulence and clinical severity 1, 2, 3. Despite being classified as a coagulase-negative staphylococcus, it must never be dismissed as a contaminant when isolated from normally sterile sites 4, 5.

Antibiotic Selection Based on Infection Type

Skin and Soft Tissue Infections (SSTI)

For simple cutaneous abscesses:

  • Incision and drainage is primary treatment 6
  • Add antibiotics if: severe/extensive disease, systemic symptoms, immunosuppression, difficult-to-drain location (face, hand, genitalia), or failure of drainage alone 6

For outpatient purulent cellulitis:

  • Clindamycin (oral, first-line) 6
  • Alternatives: TMP-SMX, doxycycline/minocycline, or linezolid 6
  • Duration: 5-10 days 6

For hospitalized complicated SSTI:

  • IV nafcillin or oxacillin (if methicillin-susceptible) 1
  • IV cefazolin (alternative for non-type 1 penicillin allergy) 1
  • IV vancomycin (if unable to tolerate beta-lactams) 1, 6
  • Duration: 7-14 days 6

Bacteremia and Endocarditis

S. lugdunensis endocarditis requires particularly aggressive management due to high rates of perivalvular extension and metastatic infection 2, 3.

For native valve endocarditis:

  • Nafcillin or oxacillin IV for minimum 4-6 weeks 1
  • Cefazolin IV (alternative for non-type 1 penicillin allergy) for 4-6 weeks 1
  • Vancomycin IV for minimum 6 weeks (if beta-lactam intolerant) 1
  • Gentamicin addition for first 3-5 days is optional but increases nephrotoxicity risk 1

For prosthetic valve endocarditis:

  • Vancomycin + rifampin + gentamicin for 6 weeks 3
  • Rifampin added after 3-5 days once bacteremia cleared 3

Critical management points:

  • Obtain follow-up blood cultures 2-4 days after initial positive cultures 7
  • Perform echocardiography on ALL patients with bacteremia (transesophageal preferred) 7, 2
  • Consult infectious disease specialist 1
  • Ensure care at facility with cardiothoracic surgery capabilities 1

Bone and Joint Infections

For osteomyelitis:

  • Nafcillin or oxacillin IV for >6 weeks 8
  • Alternatives: Vancomycin, daptomycin (6 mg/kg/day), or teicoplanin 8
  • Oral option: Levofloxacin + rifampin (most commonly used in orthopedic infections) 9, 10
  • Duration: Minimum 6 weeks 8

For septic arthritis:

  • Vancomycin IV (30-60 mg/kg/day in divided doses) for 3-4 weeks 8
  • Alternatives: Daptomycin (6 mg/kg/day), linezolid (600 mg q12h), or teicoplanin 8

For periprosthetic joint infections:

  • Requires surgical debridement (average 2 surgeries needed) 9
  • Levofloxacin + rifampin most commonly used 9, 10
  • Success rate: 89-96% with appropriate surgical and antibiotic management 9, 10

Pediatric Considerations

For children with SSTI:

  • Vancomycin IV (15 mg/kg/dose q6h) 6
  • Clindamycin (10-13 mg/kg/dose IV q6-8h) if stable and local resistance <10% 6
  • Linezolid: 600 mg q12h (>12 years) or 10 mg/kg/dose q8h (<12 years) 6
  • Avoid tetracyclines in children <8 years 6

For endocarditis/bacteremia:

  • Same beta-lactam approach as adults (nafcillin/oxacillin 4-6 weeks) 1
  • Gentamicin addition not routinely recommended 8

Antibiotic Susceptibility Profile

S. lugdunensis is typically susceptible to:

  • Vancomycin (100% susceptibility, MIC ≤0.5-1 mcg/mL) 11, 12
  • Oxacillin/nafcillin (methicillin-susceptible) 1, 12
  • Moxifloxacin 11
  • Teicoplanin 12
  • Tigecycline 12
  • TMP-SMX 12

Commonly resistant to:

  • Penicillin (75% resistance) 12

Critical Clinical Pitfalls

  1. Never dismiss as contaminant: Single positive blood cultures can represent true bacteremia, especially with intravascular devices present 4, 5. However, 81% of single-positive cultures without clinical features are contaminants 5.

  2. Predictors of true bacteremia (not contamination):

    • Presence of intravascular device (97% of significant bacteremia cases) 5
    • Multiple positive blood culture sets 5
    • Monomicrobial culture 4
    • Clinical symptoms of infection 10
  3. High endocarditis risk: Rates similar to S. aureus (16-23% of bacteremia cases) 4. Always obtain echocardiography.

  4. Shorter time to infection: Median delay between surgery and infection is shorter than S. aureus or S. epidermidis 10.

  5. Avoid vancomycin when beta-lactams possible: Beta-lactams are superior to vancomycin for methicillin-susceptible organisms 1, 3.

Duration Summary by Infection Type

  • Uncomplicated SSTI: 5-10 days 6
  • Complicated SSTI: 7-14 days 6
  • Uncomplicated bacteremia: 2 weeks (after blood culture clearance) 7
  • Complicated bacteremia: 4-6 weeks 7
  • Native valve endocarditis: 4-6 weeks minimum 1
  • Prosthetic valve endocarditis: 6 weeks 3
  • Osteomyelitis: >6 weeks 8
  • Septic arthritis: 3-4 weeks 8

References

Research

Staphylococcus lugdunensis, a serious pathogen in periprosthetic joint infections: comparison to Staphylococcus aureus and Staphylococcus epidermidis.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.